相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A New Approach to the Development ofDisease-ModifyingTherapies forPD; Fighting Another Pandemic
Karl Kieburtz et al.
MOVEMENT DISORDERS (2021)
Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease-A Pilot Study
Abhishek G. Sathe et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease
Makoto Naoi et al.
JOURNAL OF NEURAL TRANSMISSION (2020)
Brain mitochondrial impairment in early-onset Parkinson's disease with or without PINK1 mutation
Mario Rango et al.
MOVEMENT DISORDERS (2020)
Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology
Jasper C. A. Broen et al.
NATURE REVIEWS RHEUMATOLOGY (2020)
Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?
Alberto J. Espay et al.
NEUROLOGY (2020)
Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinson's disease
Phillippa J. Carling et al.
PROGRESS IN NEUROBIOLOGY (2020)
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations A Nonrandomized, Noncontrolled Trial
Stephen Mullin et al.
JAMA NEUROLOGY (2020)
Midbrain Organoids: A New Tool to Investigate Parkinson's Disease
Lisa Maria Smits et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop
Roger A. Barker et al.
JOURNAL OF PARKINSONS DISEASE (2020)
Modulation of the Microbiome in Parkinson's Disease: Diet, Drug, Stool Transplant, and Beyond
Ethan G. Brown et al.
NEUROTHERAPEUTICS (2020)
Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice
Joanna A. Korecka et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2020)
Azathioprine immunosuppression and disease modification in Parkinson's disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol
Julia C. Greenland et al.
BMJ OPEN (2020)
Isradipine Versus Placebo in Early Parkinson Disease A Randomized Trial The Parkinson Study Group STEADY-PD III Investigators
ANNALS OF INTERNAL MEDICINE (2020)
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020
Kevin McFarthing et al.
JOURNAL OF PARKINSONS DISEASE (2020)
Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease
C. V. M. Verschuur et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease
Liping Zhang et al.
JOURNAL OF PARKINSONS DISEASE (2019)
Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease
Brit Mollenhauer et al.
MOVEMENT DISORDERS (2019)
Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism
Trina Mitchell et al.
HUMAN BRAIN MAPPING (2019)
Glucocerebrosidase and its relevance to Parkinson disease
Jenny Do et al.
MOLECULAR NEURODEGENERATION (2019)
The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease
Noemie Cresto et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2019)
Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies
Mike A. Nalls et al.
LANCET NEUROLOGY (2019)
Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson's Disease
Maria Nguyen et al.
TRENDS IN NEUROSCIENCES (2019)
Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease A Secondary Analysis of the Exenatide-PD Trial
Dilan Athauda et al.
JAMA NEUROLOGY (2019)
An omics-based strategy using coenzyme Q10 in patients with Parkinson's disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial
Jannik Prasuhn et al.
NEUROLOGICAL RESEARCH AND PRACTICE (2019)
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease
Fernando L. Pagan et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2019)
Activating Autophagy as a Therapeutic Strategy for Parkinson's Disease
Alan J. Fowler et al.
CNS DRUGS (2018)
GBA-Associated Parkinson's Disease and Other Synucleinopathies
Ziv Gan-Or et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2018)
Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP/p mouse model of Parkinson's disease
Chen Qiao et al.
JOURNAL OF NEUROINFLAMMATION (2018)
β2-adrenoreceptor medications and risk of Parkinson disease
Susan Searles Nielsen et al.
ANNALS OF NEUROLOGY (2018)
Smartphone motor testing to distinguish idiopathic REM sleep behavior disorder, controls, and PD
Siddharth Arora et al.
NEUROLOGY (2018)
LRRK2 activation in idiopathic Parkinson's disease
Roberto Di Maio et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
E. Ray Dorsey et al.
LANCET NEUROLOGY (2018)
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice
Richard Gordon et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
First-in-human assessment of PRX002, an anti--synuclein monoclonal antibody, in healthy volunteers
Dale B. Schenk et al.
MOVEMENT DISORDERS (2017)
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda et al.
LANCET (2017)
New Perspectives on Study Designs for Evaluating Neuroprotection in Parkinson's Disease
Laetitia Thibault et al.
MOVEMENT DISORDERS (2017)
Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models
S. Pablo Sardi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease
Lena F. Burbulla et al.
SCIENCE (2017)
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease
Shuchi Mittal et al.
SCIENCE (2017)
The Threshold Theory for Parkinson's Disease
Simone Engelender et al.
TRENDS IN NEUROSCIENCES (2017)
Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress
Camille B. Carroll et al.
JOURNAL OF PARKINSONS DISEASE (2017)
LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model
Hien Tran Zhao et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease
Antonio Martin-Bastida et al.
SCIENTIFIC REPORTS (2017)
Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson's and Alzheimer's disease
Sandra Gellhaar et al.
CELL AND TISSUE RESEARCH (2017)
Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial
Howard E. Gendelman et al.
NPJ PARKINSONS DISEASE (2017)
Development of Passive Immunotherapies for Synucleinopathies
Ann-Louise Bergstrom et al.
MOVEMENT DISORDERS (2016)
Active immunization therapies for Parkinson's disease and multiple system atrophy
Achim Schneeberger et al.
MOVEMENT DISORDERS (2016)
A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism
Elma Aflaki et al.
JOURNAL OF NEUROSCIENCE (2016)
Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation
Milena Pinto et al.
MOLECULAR NEURODEGENERATION (2016)
Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD)
Caroline H. Williams-Gray et al.
MOVEMENT DISORDERS (2016)
Technology in Parkinson's disease: Challenges and opportunities
Alberto J. Espay et al.
MOVEMENT DISORDERS (2016)
Development and external validation of a prognostic model in newly diagnosed Parkinson disease
Daan C. Velseboer et al.
NEUROLOGY (2016)
Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3
Xiaobo Mao et al.
SCIENCE (2016)
Nilotinib Effects in Parkinson's Disease and Dementia with Lewy Bodies
Fernando Pagan et al.
JOURNAL OF PARKINSONS DISEASE (2016)
Quantitative Susceptibility Mapping in Parkinson's Disease
Christian Langkammer et al.
PLOS ONE (2016)
Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease
Aurelija Jucaite et al.
BRAIN (2015)
Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations
Roy N. Alcalay et al.
BRAIN (2015)
NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. (vol 14, pg 795, 2015)
Chadwick W. Christine
LANCET NEUROLOGY (2015)
Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration
Katrina L. Paumier et al.
NEUROBIOLOGY OF DISEASE (2015)
Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons
Emily M. Rocha et al.
NEUROBIOLOGY OF DISEASE (2015)
UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2G2019S carriers and in vivo
Heather Mortiboys et al.
NEUROLOGY (2015)
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
Tanya Simuni et al.
LANCET NEUROLOGY (2015)
Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson's Disease
Iciar Aviles-Olmos et al.
JOURNAL OF PARKINSONS DISEASE (2014)
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells
Alisdair McNeill et al.
BRAIN (2014)
Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease A Randomized Clinical Trial
Michael A. Schwarzschild et al.
JAMA NEUROLOGY (2014)
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease No Evidence of Benefit
M. Flint Beal et al.
JAMA NEUROLOGY (2014)
Inhibition of LRRK2 kinase activity stimulates macroautophagy
Claudia Manzoni et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2013)
Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease
Heather Mortiboys et al.
BRAIN (2013)
Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of -synuclein in Parkinsons disease models
Michaeline L. Hebron et al.
HUMAN MOLECULAR GENETICS (2013)
Exenatide and the treatment of patients with Parkinson's disease
Iciar Aviles-Olmos et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
α-Synuclein Vaccination Prevents the Accumulation of Parkinson Disease-Like Pathologic Inclusions in Striatum in Association With Regulatory T Cell Recruitment in a Rat Model
Vanesa Sanchez-Guajardo et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2013)
Animal Models of Parkinson's Disease: Limits and Relevance to Neuroprotection Studies
Erwan Bezard et al.
MOVEMENT DISORDERS (2013)
Interplay of LRRK2 with chaperone-mediated autophagy
Samantha J. Orenstein et al.
NATURE NEUROSCIENCE (2013)
Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson's disease
Zhongmei Chen et al.
NEUROLOGICAL SCIENCES (2013)
Modeling Lewy pathology propagation in Parkinson's disease
Kelvin C. Luk et al.
PARKINSONISM & RELATED DISORDERS (2013)
Triggering of Inflammasome by Aggregated α-Synuclein, an Inflammatory Response in Synucleinopathies
Gaia Codolo et al.
PLOS ONE (2013)
α-synuclein Imaging: A Critical Need for Parkinson's Disease Research
Jamie L. Eberling et al.
JOURNAL OF PARKINSONS DISEASE (2013)
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences
Nicole Exner et al.
EMBO JOURNAL (2012)
Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway
Li Gong et al.
JOURNAL OF NEUROCHEMISTRY (2012)
Design innovations and baseline findings in a long-term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long-Term Study-1
Jordan J. Elm
MOVEMENT DISORDERS (2012)
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease
Susan Duty et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Neuroinflammation and α-Synuclein Dysfunction Potentiate Each Other, Driving Chronic Progression of Neurodegeneration in a Mouse Model of Parkinson's Disease
Hui-Ming Gao et al.
ENVIRONMENTAL HEALTH PERSPECTIVES (2011)
Glia: Initiators and Progressors of Pathology in Parkinson's Disease
Glenda M. Halliday et al.
MOVEMENT DISORDERS (2011)
The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
E. Ilijic et al.
NEUROBIOLOGY OF DISEASE (2011)
Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death
Laura A. Volpicelli-Daley et al.
NEURON (2011)
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease
Byoung Dae Lee et al.
NATURE MEDICINE (2010)
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
E. Sidransky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The MitoPark Mouse - An animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons
Mats Ekstrand et al.
PARKINSONISM & RELATED DISORDERS (2009)
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease
Jeffrey H. Kordower et al.
NATURE MEDICINE (2008)
Use of antihypertensives and the risk of Parkinson disease
Claudia Becker et al.
NEUROLOGY (2008)
'Rejuvenation' protects neurons in mouse models of Parkinson's disease
C. Savio Chan et al.
NATURE (2007)
α-synuclein locus duplication as a cause of familial Parkinson's disease
MC Chartier-Harlin et al.
LANCET (2004)
Regulation of the C-Abl and Bcr-Abl tyrosine kinases
O Hantschel et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains
K Imamura et al.
ACTA NEUROPATHOLOGICA (2003)
Albuterol improves, response to levodopa and increases skeletal muscle mass in patients with fluctuating Parkinson disease
EY Uc et al.
CLINICAL NEUROPHARMACOLOGY (2003)
Idiopathic Parkinson's disease:: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen
H Braak et al.
JOURNAL OF NEURAL TRANSMISSION (2003)
Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic model of Huntington's disease
CD Keene et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
分享论文
